UK Medicines Agency receives injection of £10 million to expedite medicine approvals
The HM Treasury in the UK has announced that they will be awarding the Medicines and Healthcare Products Regulatory Agency (MHRA) with £10 million to expedite the generation of new medicines for UK patients.
The funding will facilitate the use of innovative medicines and new medical technologies and products, and medicines that have been approved by other regulatory bodies outside of the UK.
A framework set up by the MHRA to speed up the approval process for particularly innovative medicines will ensure that cutting-edge treatments will be more accessible to patients, as well as medicines that can be applied very quickly.
The funding will also be used to drive forward research and approval for cancer vaccines and AI-based therapeutics, which will be become more prevalent in UK medicine.
Part of the framework supports medicine use in the UK if the product has already been approved under a foreign regulatory body, thus maximising the potential of the medicine and enabling faster access to UK patients in need of the best care available.
The MHRA will still be overseeing the approval of these other medicines via the framework, to ensure UK standards of quality and safety are still met, whilst improving patient access.
The first partners who will be involved in these ‘recognition routes’ with the MHRA are the US FDA and the Japan-based PMDA, relationships that have been cultivated via the Access Consortium and Project Orbis.
Dr June Raine, MHRA Chief Executive, stated:
“We greatly welcome the £10 million funding announced by HM Treasury today, which will be used to fund our ongoing innovation work and to accelerate the development of ground-breaking global recognition routes, which will give UK patients faster access to the most cutting-edge medical products in the world.
“This cash injection will ensure that we have access to the best resources, talent, and infrastructure to deliver this ambitious vision for patients across the UK.”
Steve Barclay, Secretary of State for Health and Social Care, added:
“Technology is transforming our care for patients, delivering faster and more accurate diagnoses. This new funding will accelerate the delivery of cutting-edge treatments like cancer vaccines and new artificial intelligence technology that will make therapy more accessible to those who suffer from mental health conditions.
“It will also fast-track access to medical products that have been approved in other countries by trusted regulatory partners, ensuring we continue to provide the best, most innovative and safest treatments in the UK.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company
After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. -
News PharmaKure gains authorisation for next stage testing on Alzheimer's treatment
Clinical stage pharmaceutical company PharmaKure gains permission from UK authorities to enter into further testing for PK051 for the treatment of patients with mild cognitive impairment associated with Alzheimer's disease. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News Navigating the Future: Challenges and Opportunities in Pharma Innovation and Investment – CPHI Barcelona 2023 Roundtable Report
In this comprehensive downloadable report, hear from a range of experts in finance and investment in the pharma industry on what investment trends will be shaping the future of the industry, in Catalonia, and the wider world. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance